Physician profile
Igor Sobol
NPI 1992858112
$55,151.17
in general payments reported to CMS, 2019-2025
40 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,919 · 2020: $16K · 2021: $18K · 2022: $7,754 · 2023: $5,977 · 2024: $4,185 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,800 · Food and Beverage: $3,452 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,800.00 |
| Food and Beverage | $3,451.50 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $29,762.33 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Allergan, INC. | $19,250.57 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,030.08 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $936.49 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Biohaven Pharmaceuticals, INC. | $749.00 | 2021 | |
| Neurocrine Biosciences, INC. | $474.11 | 2019-2025 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $324.63 | 2019-2021 | |
| Lundbeck LLC | $324.15 | 2022-2024 | Vyepti |
| Biogen, INC. | $283.86 | 2019-2022 | |
| Axsome Therapeutics, INC. | $250.08 | 2025 | Symbravo |
| Eisai INC. | $220.30 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $195.58 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $194.04 | 2022 | |
| Amgen INC. | $168.85 | 2019-2022 | |
| Argenx US, INC. | $130.01 | 2024-2025 | Vyvgart Hytrulo |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Sobol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.